First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States

Overview of attention for article published in Frontiers in Pharmacology, July 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 7 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,184 followers.

RT @FrontPharmacol: New Research: First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-sma…

20 Jul 2023

Reply Repost Favourite

New Research: First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States #pharmacology https://t.co/Ha3GCnIVY4

20 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.